The Goldman Sachs Group Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $75.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective increased by research analysts at The Goldman Sachs Group from $60.00 to $75.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price would suggest a potential upside of 19.35% from the stock’s current price.

Several other research firms have also weighed in on KNSA. Wells Fargo & Company lifted their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, June 29th. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $68.00.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $62.84 on Thursday. The business has a 50 day simple moving average of $56.87 and a 200 day simple moving average of $49.97. Kiniksa Pharmaceuticals International has a one year low of $26.27 and a one year high of $67.53. The stock has a market capitalization of $4.83 billion, a P/E ratio of 69.82 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 earnings per share. Equities analysts expect that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, insider John F. Paolini sold 58,424 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the transaction, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the completion of the sale, the chief executive officer directly owned 431,904 shares of the company’s stock, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 628,427 shares of company stock valued at $32,833,228 over the last ninety days. 51.98% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after acquiring an additional 90,194 shares in the last quarter. Vanguard Group Inc. lifted its position in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after acquiring an additional 49,802 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after purchasing an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd boosted its stake in Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.